PRISM Plus tirofiban and heparin in the treatment of unstable angina and nonQwave myocardial infarction

PRISM-PLUS: Demographics of Patients With Diabetes Patients Without Diabetes (n=1208) Mean age (y) Prior MI Patients With Diabetes (n=362) 66 47% 62 40% Heart failure PTCA CABG 7% 31% 23% 16% 28% 24% PRISM-PLUS: MI/Death Outcomes in Patients With Diabetes Heparin (n=193) P=0.044 P=0.002 15.5% 19.2% 20 Tirofiban + heparin (n=169) % Patients 15 P=0.004 11.2% 9.3% 4.7% 10 5 1.2% 0 Day 7 Day 30 Day 180 PRISM-PLUS: MI in Patients With Diabetes Heparin (n=193) 20 Tirofiban + heparin (n=169) P=0.008 P=0.002 % Patients 15 13.5% P<0.001 10 7.8% 11.4% 5 1.8% 0 0% Day 7 Day 30 4.7% Day 180 PRISM-PLUS: Results in Patients With Diabetes Conclusion Tirofiban + heparin therapy resulted in a marked sustained reduction in major cardiac outcomes, particularly recurrent MI, in patients with diabetes presenting with UAP/NQWMI.